Connect with us

COVID-19

Wuhan lab’s U.S. partner questioned about COVID viral load manipulation

Published

on

Coronavirus

Wuhan Institute of Virology – along with its U.S. partner – manipulated the COVID virus in violation of regulations established by the National Institutes of Health. The manipulation of the virus allowed the it to to generate up to 10,000 times the viral load, according to information provided in a letter from the NIH to House Republicans.

This new information puts to rest claims that the virus was not manipulated to be more lethal and is a vindication to those that questioned Dr. Anthony Fauci’s earlier allegations that the NIH did not fund research.

In the NIH letter the agency stated that EcoHealth ( the US partner) violated provisions in its contract “requiring to report to government funders should one of the viruses in its experiment product ‘a one log increase in growth.’ The company did not report the increase. Instead, it worked with the Wuhan lab, and created extraordinary growth in the virus load from 1,000 fold to 10,000 fold. This increase led to severe disease in mice and deaths in the laboratory, according to reports.

News outlets that shunned those who questioned whether the virus was manipulated should be called out for their failure to do their job. Remember, questioning something does not make you a conspiracy theorist. In fact, asking questions and holding the government, agencies and departments accountable is wise and necessary for truth in any Democracy.

From Roll Call:

“NIH said the nonprofit partner, EcoHealth Alliance, must submit any unpublished data to the agency by Monday to come back into compliance with its NIH grant. Any new documents could shed further light on the controversial nonprofit’s research.

The EcoHealth project ran afoul of NIH terms because it experimented with changing the spike protein of a bat coronavirus identified by researchers as “poised for human emergence” and tested how well it infected human airway cells, according to the letter released by House Oversight and Reform ranking member James R. Comer, R-Ky., late Wednesday. The committee also released a long overdue progress report detailing the group’s work from 2018 to 2019. EcoHealth, a New York-based intermediary between the NIH and the Wuhan Institute of Virology, did not submit it to NIH until August.”

You may like

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.

China

China Says It’s Ready for Monkeypox and the West Isn’t

Published

on

China

As the Western press is becoming more and more concerned with monkeypox outbreaks, a recent bombshell report shows that Wuhan Institute of Virology (WIV) in China manipulated monkeypox to be more contagious in humans. This follows more evidence that the WIV had been experimenting with bat coronaviruses to increasingly infect humans.

But rather than agree to an honest investigation into the WIV and its role in spreading contagion around the world, China is once again trying to sell us an alternative reality. According to Chinese state-run media, it is China that is once again poised to be humanity’s savior and darling when it comes to fighting monkeypox, much like COVID-19. Not only that, but CCP press reporting shows evidence of China having an eerily well advanced infrastructure and gameplan to fight monkeypox. The West in contrast is not prepared, according to China.

Claim #1: China has the Wisdom to Fight Monkeypox

First, Chinese state-run media portray China as in a good position to combat monkeypox due to wisdom gleaned from combating COVID-19 and smallpox. One Global Times article noted that “[i]n the very early stage of the COVID-19 pandemic, China has taken the measures of ‘early identification, reporting, isolation, diagnosis and treatment.’ Under such guidance, China has become one of the most successful countries in the COVID fight.” Another Global Times article cites a World Health Organization official as stating that “China’s COVID-19 control measures in place and largely reduced international arrivals minimize the risks of contagion in China.” A third Global Times article, citing “experts,” claims that “China’s successful experience in eliminating smallpox would also help the country act if monkeypox enters China’s borders…”

Claim #2: Chinese Healthcare Infrastructure Is Well Prepared to Deal with Monkeypox

China is well ahead of the game in dealing with monkeypox, according to Chinese state-run media. Chinese experts “suggest preparation of testing and treatment capacities in advance” to proactively combat monkeypox, according to Global Times. And “drug research should start early so that China can still control [monkeypox] should it assume pandemic proportions,” according to China Daily.

China is apparently quite far along in this “preparation” and “research.”

There are “several” Chinese manufacturers that have already made monkeypox nucleic acid test kits, and that these “can be quickly put into mass production and on the domestic market once approved by the government,” according to a second Global Times article.  This article also states that Chinese manufacturer Liferiver Bio-Tech has a nucleic acid test that has already been ordered in China and abroad.

This same article also states that vaccine development faces “no technological problems” and a vaccine can be produced in China in a year if China’s drug administration administers “a rapid special review.” China’s CDC also has already stockpiled “millions” of doses of smallpox vaccine, produced “an emergency response technical plan on monkeypox, stocked monkeypox detection reagents, and conducted training on monkeypox nucleic acid PCR testing for provincial and municipal CDC professionals.”

Mirroring its earlier “mask diplomacy” for COVID-19, it looks like China is beginning to export its healthcare to the world to help combat monkeypox. China’s Sansure Biotech is ready to register its nucleic acid test kit for monkeypox abroad, according to Global Times. And Jiangsu Bioperfectus Technologies has already has its Monkeypox Virus Real Time PCR Kits in the international market, according to Global Times.

Claim #3: The West is Ill-Equipped to Handle Monkeypox

On the other hand, Chinese media portrays the West as ill-equipped to handle monkeypox. For example, according to one Global Times editorial, “[t]he COVID pandemic that killed more than 1 million people in the US has given a tragic lesson to the US and the West, but it still remains to be seen to what extent the US and the West learned from it.” The West’s “conspiracy theories” and “panic” contributed to the “Western countries’ poor response to COVID-19.” That CCP editorial also pontificates that “[i]t is hoped that Western countries hit by monkeypox can do a good job in responding to the outbreak. They should not misjudge the virus with outdated perceptions…”

Claim #4: Current Monkeypox spread originated from outside China

Chinese media avoids the possibility that this current monkeypox outbreak could have originated in China. One Global Times article claims that there have been no cases of monkeypox reported in China, and that China faces a threat from monkeypox due to the cases being “outside known epidemic areas of Africa.” The fact that many countries have now lifted bans against international travel is the culprit for increased risk of monkeypox transmission, according to anonymous source within the Chinese CDC as mentioned in that same article. Another Global Times article stated that China could quarantine inbound international travellers “if necessary.”

The CCP propaganda machine is at it again.  Much like it tries to portray itself as a leader in fighting COVID-19, China is beginning to run a similar propaganda campaign for monkeypox. China is using COVID-19, and increasingly now monkeypox, as vehicles to curry favor and deflect responsibility for spreading contagion around the world, and to grow markets for healthcare technology and supplies.

You may like

Continue Reading
Advertisement

Trending Now

Advertisement

Trending

Proudly Made In America | © 2022 M3 Media Management, LLC